Pacira Pharmaceuticals (PCRX) AI Stock Analysis

• Market Cap: $1.08B
• Dividend Yield: N/A
• Average Volume (3M): 571.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 3.08%
• EPS Growth: -247.82%
• Country: US
• Employees: 788
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.62
• Shares Outstanding: 46,304,670
• 10 Day Avg. Volume: 554,173
• 30 Day Avg. Volume: 571,337
• PEG Ratio: 0.23
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.18
• Enterprise Value/Market Cap: 2.00
• Enterprise Value/Revenue: 0.77
• Enterprise Value/Gross Profit: 4.17
• Enterprise Value/Ebitda: 8.90
• 1Y Price Target: $41.25
• Price Target Upside: 77.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 59 Neutral
• Price Target: $25.00 ▲(7.71%Upside)

Pacira's overall stock score of 59 reflects solid strategic progress and positive sentiment from its earnings call, which is offset by challenges in profitability and bearish technical indicators. Significant efforts in growth and innovation are promising, but financial stability needs improvement.

Positive Factors

Patent Litigation

Pacira announced a settlement on Exparel patent litigation, which is viewed as a positive for the stock.

Revenue Growth

Revenue growth is expected to accelerate with NOPAIN driving higher volumes, and the settlement is seen as key to unlocking a re-rate in the stock's valuation multiple.

Share Repurchase Program

A new $300MM share repurchase program has been announced.

Negative Factors

Competitive Pressures

There are concerns about competitive pressures impacting Pacira's market share.

Regulatory Challenges

Regulatory challenges could pose risks to Pacira's upcoming product launches.

Sales Growth Uncertainty

Investors looking for an inflection in Exparel sales growth, but this could take longer than hoped as the NOPAIN Act is likely not a 'light switch' nor the 'silver bullet'.

Pacira Pharmaceuticals Business Overview & Revenue Model

Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

How the Company Makes Money

Pacira Pharmaceuticals generates revenue primarily through the sale of its core product, EXPAREL, which is widely used in hospitals and surgical centers to manage post-surgical pain. The company's revenue model is centered on the distribution and commercialization of EXPAREL, which is marketed directly to healthcare providers. Additionally, Pacira may generate income through partnerships and collaborations with other pharmaceutical companies, aimed at expanding the application of their products and enhancing market penetration. The company's earnings are significantly influenced by factors such as regulatory approvals, market adoption of non-opioid pain management solutions, and ongoing clinical research to support the efficacy and safety of its products.

Pacira Pharmaceuticals Financial Statement Overview

Summary

Pacira Pharmaceuticals showcases stable revenue growth and strong gross margins but faces significant challenges with profitability and high leverage. Although cash flow generation is strong, high debt levels and negative net income negatively impact the financial outlook.

Income Statement

Pacira Pharmaceuticals shows a modest revenue growth in the TTM with a 0.26% increase from the previous year. However, profitability metrics are concerning, with negative EBIT and net profit margins, indicating operational challenges. The gross profit margin remains healthy at approximately 73.6%, suggesting strong core business profitability despite overall losses.

Balance Sheet

The company's balance sheet reflects a somewhat stable position with an equity ratio of 50.3%, indicating moderate reliance on debt. However, the debt-to-equity ratio is high at 0.8, suggesting potential risk from leverage. Despite these challenges, the return on equity is negative, impacted by the net loss, which is a concern for future profitability.

Cash Flow

Operating cash flow remains robust, with an operating cash flow to net income ratio of -1.69, indicating strong cash generation relative to accounting losses. The free cash flow growth rate is negative year-over-year, but the company still maintains a positive free cash flow, which is a positive sign for liquidity management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	266.65M	700.97M	674.98M	666.82M	541.53M	420.83M
Gross Profit	187.99M	530.54M	490.31M	467.53M	401.28M	303.50M
EBITDA	5.30M	32.25M	157.58M	144.78M	118.47M	71.42M
Net Income	-11.22M	-99.56M	41.95M	15.91M	41.98M	145.52M
Balance Sheet
Total Assets	719.16M	1.55B	1.57B	1.68B	2.08B	1.27B
Cash, Cash Equivalents and Short-Term Investments	412.44M	484.62M	278.58M	288.65M	656.41M	521.66M
Total Debt	329.24M	638.85M	586.04M	763.39M	1.13B	541.13M
Total Liabilities	391.64M	775.17M	704.26M	906.19M	1.34B	654.83M
Stockholders Equity	327.52M	778.35M	870.13M	775.01M	730.41M	619.69M
Cash Flow
Free Cash Flow	-10.38M	178.75M	139.49M	115.20M	79.85M	39.23M
Operating Cash Flow	24.27M	189.39M	154.65M	145.27M	125.72M	77.03M
Investing Cash Flow	-41.10M	-83.28M	77.54M	-225.19M	-20.79M	-277.61M
Financing Cash Flow	9.42M	17.36M	-183.03M	-401.53M	380.69M	222.30M

Pacira Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Negative. The current price of 23.21 is below the 20-day moving average (MA) of 24.55, below the 50-day MA of 25.30, and above the 200-day MA of 21.70, indicating a neutral trend. The MACD of -0.55 indicates Positive momentum. The RSI at 35.27 is Neutral, neither overbought nor oversold. The STOCH value of 18.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCRX.

Pacira Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCRX	59 Neutral	$1.08B	―	-12.27%	―	3.08%	-247.82%
INVA	57 Neutral	$1.24B	89.44	-8.84%	―	17.90%	-133.73%
VRDN	55 Neutral	$1.18B	―	-49.41%	―	4.86%	10.13%
OPK	52 Neutral	$1.05B	―	-3.04%	―	-13.79%	82.82%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
SNDX	48 Neutral	$758.94M	―	-93.70%	―	―	-25.83%
IOVA	48 Neutral	$581.05M	―	-51.85%	―	11070.12%	32.07%

Pacira Pharmaceuticals Corporate Events

Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan

On June 10, 2025, Pacira BioSciences, Inc. held its Annual Meeting of Stockholders in Parsippany, New Jersey, where stockholders approved the Amended and Restated 2011 Stock Incentive Plan, increasing the number of shares authorized for grant by 2,500,000. Additionally, the meeting included the election of directors, ratification of KPMG LLP as the accounting firm, and decisions on executive compensation, with the board opting for annual advisory votes on executive pay, reflecting a commitment to good corporate governance.

The most recent analyst rating on (PCRX) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.

Pacira Pharmaceuticals Settles Patent Litigation with Fresenius

On April 7, 2025, Pacira BioSciences announced a settlement with Fresenius Kabi and others regarding patent litigations for EXPAREL®, allowing Fresenius to sell limited volumes of a generic version in the U.S. starting in 2030, with unlimited sales permitted from 2039. This agreement resolves ongoing litigations, provides clarity on EXPAREL’s exclusivity, and involves a $7 million payment to Fresenius, potentially impacting Pacira’s market strategy and stakeholder interests.